List of publications utilizing CHIR 98014 - CT 98014 (Axon 1126) purchased from Axon Medchem 

(Total 18 publication citations listed; updated AUGUST-2017)

2014
Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors.
Naujok O, Lentes J, Diekmann U, Davenport C, Lenzen S.
BMC Res Notes. 2014 Apr 29;7:273. doi: 10.1186/1756-0500-7-273.

2013
Method for manufacturing pancreatic-hormone-producing cells
M Hosoya, Y Kunisada, M Shoji, N Yamazoe. 
European Patent Application EP2505639; United States Patent Application 20130022986

Culture medium for pluripotent stem cells.
J Wu, QL Ying, H Kim
United States Patent Application 20130273649 A1.

Control of Aβ release from human neurons by differentiation status and RET signaling.
Scholz D, Chernyshova Y, Leist M.
Neurobiol Aging. 2013 Jan;34(1):184-99. doi: 10.1016/j.neurobiolaging.2012.03.012. Epub 2012 Apr 24.

A Small Molecule Screen in Stem-Cell-Derived Motor Neurons Identifies a Kinase Inhibitor as a Candidate Therapeutic for ALS. 
Yang YM, Gupta SK, Kim KJ, Powers BE, Cerqueira A, Wainger BJ, Ngo HD, Rosowski KA, Schein PA, Ackeifi CA, Arvanites AC, Davidow LS, Woolf CJ, Rubin LL.
Cell Stem Cell. 2013 Jun 6;12(6):713-26. doi: 10.1016/j.stem.2013.04.003. Epub 2013 Apr 18.

2012
N-cadherin specifies first asymmetry in developing neurons.
Gärtner A, Fornasiero EF, Munck S, Vennekens K, Seuntjens E, Huttner WB, Valtorta F, Dotti CG.
EMBO J. 2012 Apr 18;31(8):1893-903. doi: 10.1038/emboj.2012.41. Epub 2012 Feb 21.

Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome. 
Balmer NV, Weng MK, Zimmer B, Ivanova VN, Chambers SM, Nikolaeva E, Jagtap S, Sachinidis A, Hescheler J, Waldmann T, Leist M.
Hum Mol Genet. 2012 Sep 15;21(18):4104-14. doi: 10.1093/hmg/dds239. Epub 2012 Jun 20.

Method for constructing chimeric rat using rat embryonic stem cells.
T Ochiya, M Kawamata. 2012.
US Patent Application 20120272349; European Patent Application EP2508595

2011
Use of WNT stimulators for treating demyelinating diseases.
Centre National de la Recherche Scientifique (CNRS). 2011.
EP Patent application. EP2305274 (A1).

A screen for regulators of survival of motor neuron protein levels.
Makhortova NR, Hayhurst M, Cerqueira A, Sinor-Anderson AD, Zhao WN, Heiser PW, Arvanites AC, Davidow LS, Waldon ZO, Steen JA, Lam K, Ngo HD, Rubin LL.
Nat Chem Biol. 2011 Jun 19;7(8):544-52. doi: 10.1038/nchembio.595.

Volatile anesthetic post-treatment induces protection via inhibition of glycogen synthase kinase 3β in human neuron-like cells.
D. Lin, G. Li, Z. Zuo.
Neuroscience. 2011 Apr 14;179:73-9. doi: 10.1016/j.neuroscience.2011.01.055. Epub 2011 Jan 28.

Method of producing pancreatic hormone-producing cells. 
M. Hosoya, S. Masanobu, 2011.
European Patent Application EP2604685 (A4)

Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation.
Selenica ML, Jensen HS, Larsen AK, Pedersen ML, Helboe L, Leist M, Lotharius J.
Br J Pharmacol. 2007 Nov;152(6):959-79. Epub 2007 Oct 1.
*CHIR 98014 used in this article was custom-synthesized at Axon Medchem.

(This is an incomplete list, updated in AUGUST-2017)